PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,668,893 | polym surfac ligand silica coat induc high stabl perovskit nanocryst enhanc aqueous fluoresc effici hg glutathion detect poor stabil aqueous quench fluoresc perovskit nanocryst ncs hinder applic bio detect bio imag herein synergist effect polym surfac ligand silica encapsul high stabl enhanc aqueous fluoresc cspbbr mpeg sio ncs synthes use novel fluoresc probe high sensit select detect mercuri ion hg glutathion gsh aqueous solut effect methoxypolyethylen glycol amin mpeg nh ligand silica encapsul stabil aqueous fluoresc cspbbr ncs studi indic aqueous fluoresc perovskit ncs increas time water stabil also great improv ncs maintain origin fluoresc storag day water x ray diffract xrd transmiss electron microscopi tem fourier transform infrar spectroscopi ft ir analys demonstr ncs success passiv mpeg nh silica fluoresc cspbbr mpeg sio nanocryst effect quench hg attribut electron transfer process ncs hg interact hg gsh restor fluoresc cspbbr mpeg sio realiz fluoresc probe use detect hg gsh low detect limit nm respect also show fast respons time high accuraci practic sampl detect simpl sensit fluoresc probe cspbbr mpeg sio show great potenti environment biolog sens | D008628;D053758 | T131;T073;T196 |
34,668,892 | investig potenti mix solvent mobil phase temperatur respons liquid chromatographi trlc temperatur respons liquid chromatographi trlc allow extens retent select tune temperatur hplc main achiev use stationari phase compris temperatur respons polym undergo revers chang hydrophil hydrophob behaviour upon increas temperatur approach allow revers phase type separ achiev pure aqueous mobil phase wherebi retent control temperatur instead mobil phase composit despit promis natur form retent control isocrat mobil phase condit trlc suffer excess retent high apolar solut even lower column temperatur wherebi polym consid hydrophil relat residu apolar polym chain due high log p low water solubl hig apolar compound known elut trlc nt necessarili perform pure aqueous condit use organ co solvent water possibl impact thereof temperatur respons behaviour yet investig systemat way therefor work advantag drawback use organ co solvent methanol acetonitril trlc assess two type temperatur repons phase poli n n propylacrylamid pnnpaam poli n isopropylacrylamid pnipaam influenc organ co solvent investig two repres test mixtur compris paraben apolar steroid | D012997 | T130 |
34,668,890 | ethic legal social implic fetal gene therapi fetal gene therapi move experiment anim model human utero phase clinic trial need consid ethic legal social implic fetal gene therapi attract regulatori oversight previous fetal intervent fetal surgeri old sociolog question appli new context health care pathway around fetal therapi shape way pregnant person fetus constitut risk benefit evalu afford lose sight long term consequ especi pertain social inclus | D004992;D046128 | T061;T078 |
34,668,889 | utero fetal therapi stem cell cell transplant gene therapi crispr cas utero fetal therapi offer opportun prevent treat diseas cellular genet basi compon success fetal treatment includ isol replac cell popul utero stem cell transplant cell engraft fetal immun toler ongo cell function fetal gene therapi crispr cas repres excit potenti therapi genet diseas amen gene supplement via adenovir vector transduct fetal therapi uniqu ethic safeti consider clinic trial utero cell therapi underway addit discoveri stem cell biolog gene therapi move closer clinic translat | D005315;D046128;D018380 | T047;T061 |
34,668,887 | elimin hormon oral activ gonadotropin releas hormon antagonist gonadotropin releas hormon gnrh analogu use clinic practic near decad begin gnrh agonist agent use treat hormon depend diseas suppress gonadotropin product assist reproduct technolog develop gnrh antagonist especi small molecul antagonist abil achiev gonadotropin sex steroid suppress becom increas effect conveni review briefli describ develop gnrh analogu review evolut oral activ small molecul gnrh antagonist provid overview expand role small molecul gnrh antagonist clinic practic | D007987;D006727 | T116;T121;T125 |
34,668,886 | hormon contracept system estrogen progestin prepar combin hormon contracept chc short act revers method contain estrogen progestin avail chc method includ combin oral contracept transderm patch vagin ring combin oral contracept remain common use contracept method unit state general principl chc review includ mechan action effect unless otherwis state principl appli chcs discuss clinic studi specif consider relat pill patch ring method specifi word specifi sex use discuss studi sex specifi | D003278;D011372 | T039;T121;T125 |
34,668,884 | menopaus transit mongolia purpos cross section pilot studi develop preliminari understand menopaus experienc mongolian women goal collect symptom associ end menstruat understand languag use mean menopaus everyday life | D019584;D008593 | T039;T184 |
34,668,883 | handgrip strength dynapenia relat factor postmenopaus women studi aim evalu preval dynapenia factor relat low domin handgrip strength hgs postmenopaus women | D018737;D010024 | T040;T047;T081 |
34,668,878 | combin therapi long act inject second generat antipsychot oral antipsychot retrospect chart review prescrib attitud survey although long act inject antipsychot lai ap consid monotherapeut option mainten treatment schizophrenia recent report combin therapi lai ap oral antipsychot oap common | D001291;D011307 | T058;T170;T041 |
34,668,872 | effect smartphon base communiti case manag urgent referr reconsult hospit children age year malawi cluster random step wedg trial integr communiti case manag ccm led reduct child mortal malawi result ill malaria pneumonia diarrhea howev adher ccm guidelin often poor potenti lead inappropri clinic decis poor outcom determin impact e ccm app referr reconsult hospit rate children present villag clinic malawi | D019090;D000068997 | T058;T073 |
34,668,868 | fev matter person goal reach along way qualit multicent prospect observ studi covid pandem boost use forc expiratori volum second fev telemonitor pediatr asthma consensus effici effect implement still lack find answer import studi intervent perceiv experienc use patient health care profession hcps | D000086382;D006040 | T047;T170;T067 |
34,668,865 | eyelid myoclonia absenc relat epilept negat myoclonus eyelid myoclonia absenc ema epilept syndrom characteris eyelid myoclonia without absenc eye closur induc paroxysm photosensit relationship ema epilept negat myoclonus previous report herein describ case year old girl present eyelid myoclonia eye closur induc paroxysm photosensit compat diagnosi ema ictal eeg depict eye closur induc diffus hz polyspik wave complex accompani eye flutter eyelid myoclonia emg disclos brief interrupt msecond tonic contract orbiculari oculi muscl associ polyspik wave complex eeg find led diagnosi epilept negat myoclonus eye closur induc eyelid epilept negat myoclonus demonstr patient may atyp seizur type ema repres intermedi eyelid myoclonia epilept negat myoclonus | D005143;D009207 | T047;T023;T184 |
34,668,863 | intracort focal non convuls status epilepticus caus cerebr hypoxia intracrani hypertens describ pathophysiolog consequ long term neurolog outcom patient acut brain injuri abi intracort electroencephalographi ieeg captur episod prolong focal non convuls status epilepticus ncse remain undetect scalp electroencephalographi year old right hand woman admit hospit due larg frontal left intraparenchym hematoma two half day captur recurr non convuls electrograph electroclin seizur compat diagnosi intracort focal ncse patient remain sedat burst suppress pattern obtain also perform invas brain multimod monitor includ ieeg measur intracrani pressur icp partial brain tissu oxygen pbto brain temperatur non convuls electrograph electroclin seizur valu pbto decreas icp increas six month later brain mri reveal encephalomalacia local left paramedi fronto basal region neuropsycholog assess carri one year injuri show score averag verbal learn memori motor dexter execut function summari ieeg feasibl innov invas techniqu may use record non convuls electrograph electroclin seizur remain invis surfac intracort focal ncse caus metabol chang reduc brain oxygen increas icp damag previous compromis brain tissu | D002534;D019586;D013226 | T033;T046;T047 |
34,668,857 | room tilt illus epilepsi room tilt illus rare phenomenon person transient perceiv surround environ tilt one side epilepsi one presum caus room tilt illus never proven present case room tilt illus epilept natur document video eeg monitor patient year old woman year histori bi month spell sudden tilt whole environ counterclockwis durat one two second spell initi diagnos psychogen admit video eeg monitor unit three typic spell monitor correspond chang brief general spike wave burst eeg coincid temporarili symptom video otherwis reveal sway tilt patient start topiram resolut symptom remain spell free seen follow six month later case illustr first exampl room tilt illus document epilept natur case add vari natur epilepsi manifest patient may support improv diagnosi treatment epilept patient | D004827;D007088 | T033;T048;T047;T041 |
34,668,855 | high seropreval anti denv igm blood donor earli outbreak feder district brazil dengu endem brazil sever brazilian citi affect frequent season outbreak diseas outbreak possibl transfus transmit dengu ttd increas main presenc asymptomat oligosymptomat infect elig blood donor retrospect assess anti denv igm ns seropreval given time interv may indic need measur previous screen denv infect blood donor context perform retrospect screen anti denv igm ns blood donor feder district brazil earli outbreak occur largest outbreak recent year total blood donat screen anti denv igm denv ns use commerci enzym link immunosorb assay kit panbio dengu igm captur elisa platelia dengu ns ag respect among test plasma sampl present anti denv igm sampl present denv ns despit appar absenc antigenaemia test blood donat high preval anti denv igm highlight import denv screen blood donor princip outbreak period | D001782;D003715;D004196 | T061;T047;T098;T067 |
34,668,854 | hanstruepera crassostrea et al later heterotyp synonym pseudobizionia ponticola park et al hanstruepera crassostrea l compar pseudobizionia ponticola mm examin taxonom relationship two type strain rrna gene sequenc h crassostrea l complet similar p ponticola mm result phylogenet analys base rrna gene sequenc indic two strain form tight cluster within genus pseudobizionia draft genom comparison two strain reveal averag nucleotid ident digit dna dna hybrid estim strong indic two strain repres singl speci addit neither strain display strike differ metabol physiolog chemotaxonom featur therefor propos hanstruepera crassostrea later heterotyp synonym pseudobizionia ponticola | D010802 | T062;T078 |
34,668,852 | antibiot resist presenc bla cfxa bla csp gene lactamas produc clinic capnocytophaga isol univers hospit japan introduct capnocytophaga speci common inhabit oral caviti respons system diseas immunocompromis patient granulocytopenia furthermor report clinic isol capnocytophaga speci produc extend spectrum lactamas esbl gap statement inform lack type lactamas gene possess capnocytophaga spp antimicrobi suscept capnocytophaga spp possess lactamas gene aim aim studi investig presenc lactamas gene clinic strain lactamas produc capnocytophaga speci isol clinic sampl acquir shinshu univers hospit examin antimicrobi suscept strain methodolog lactamas produc capnocytophaga speci n obtain clinic specimen pcr assay use detect bla cfxa bla csp bla tem bla cepacbla transposon tn gene southern hybrid assay use detect bla cfxa bla csp minimum inhibitori concentr lactam determin use e test method result pcr analysi indic bla cfxa gene present bla csp gene capnocytophaga strain investig bla cfxa bla csp gene detect capnocytophaga gingivali strain pcr result confirm southern hybrid assay transposon tn detect capnocytophaga spp harbour bla cfxa gene lactamas produc capnocytophaga isol suscept ceftazidim clavulan acid cefoxitin imipenem contrast isol resist amoxicillin conclus clinic isol capnocytophaga spp show high preval bla csp gene japan presenc bla csp gene distribut capnocytophaga sputigena well capnocytophaga spp result seem suggest dissemin bla cfxa bla csp lactamas gene among capnocytophaga speci | D004352 | T032 |
34,668,850 | vitro activ bedaquilin mycobacterium avium complex introduct nontubercul mycobacteria ntm widespread environ caus various diseas human especi immunocompromis patient hypothesi treatment diseas caus ntm complic issu main due resist pathogen antimicrobi agent bedaquilin bdq wide use treatment multidrug resist mdr extens drug resist xdr tuberculosi tb aim main goal studi evalu activ bdq mycobacterium avium complex mac common speci among ntm methodolog total mac cultur mycobacterium avium mycobacterium intracellular studi minimum inhibitori concentr mic bdq avium intracellular obtain twofold serial dilut middlebrook h medium mic rang determin mic mic ecoff valu obtain result mic respect avium rang g ml intracellular rang g ml bdq mic mic valu found g ml respect avium g ml respect intracellular tentat ecoff valu avium intracellular g ml respect conclus main bedaquilin suscept paramet mac strain isol moscow region determin | D024881;D015270 | T032;T047 |
34,668,849 | flavobacterium hydrocarbonoxydan sp nov isol pollut soil paper present polyphas taxonom studi gram stain negat bacterium design ga soil isol capabl benzo pyren degrad phylogenet analysi base rrna gene sequenc indic strain ga member genus flavobacterium form independ phylogenet line cluster type strain flavobacterium hibernum flavobacterium branchiarum flavobacterium hydati strain ga facult anaerob could grow c optimum c ph optimum ph presenc wv nacl optimum strain ga capabl produc acid various carbon sourc compar relat speci flavobacterium strain contain mk isoprenoid quinon iso c major cellular fatti acid phosphatidylethanolamin phosphatidylinositol diagnost polar lipid sym homospermidin major polyamin chemotaxonom properti strain ga consist general properti flavobacterium except presenc phosphatidylinositol distinguish relat speci total stretch obtain genom ga mbp dna gc content mol genom contain gene potenti relat degrad aromat hydrocarbon basi present polyphas analysi strain ga found properti distunguish repres novel speci genus flavobacterium name flavobacterium hydrocarbonoxydan sp nov propos type strain ga kctc lmg | D005417;D010802;D012988 | T007;T062;T067;T078 |
34,668,847 | effect manual therapi patient distal radius fractur systemat review meta analysi determin effect manual therapi mt function outcom patient distal radius fractur drf | D026201;D011885 | T037;T061 |
34,668,846 | reactiv oxygen speci nitric oxid mediat plant hypersensit respons stomat closur nitric oxid reactiv oxygen speci ros attract consider interest plant pathologist sinc regul plant defens via hypersensit respons hr stomat closur introduc regulatori mechan ros burst discuss role burst hr stomat closur show epiderm section leav respond pathogen rapid intens product intracellular ros oxid stress h induc stomat closur catalas peroxidas defici plant also hyperrespons pathogen invas suggest role h hr mediat cell death analysi reveal ros play import role stomat closur hr involv multipl pathway therefor multi disciplinari multi omic combin analysi crucial advanc ros research role plant defens mechan | D017360;D009569 | T121;T002;T197 |
34,668,845 | sexual satisfact cognit schema activ sexual context among iranian marri women reproduct age present studi examin relationship sexual satisfact ss cognit schema activ sexual context cross section studi particip compris iranian marri women mean age year mean marriag durat year data collect util onlin survey compris index sexual satisfact cognit schema activ sexual context questionnair number sociodemograph question linear regress model util stepwis method perform mean score cognit schema relat sexual problem sd highest mean differenceloneli subscal higher score indic greater negat schema activ mean score sexual satisfact iss sd highest score cognit schema relat sexual problem observ among individu low sexual satisfact base multivari linear regress model age spous social support spous job highest regress coeffici relat sexual satisfact among iranian marri women cognit schema activ sexual context strong signific associ sexual satisfact among iranian marri women reproduct age find suggest schema therapi techniqu use alongsid initi promot spous social support help prevent problemat sexual cognit schema | D008393;D009948 | T079;T055;T072;T041;T054;T081;T040;T033;T062;T080 |
34,668,842 | product review mab alemtuzumab ocrelizumab treatment multipl sclerosi tradit manag activ relaps remit ms base call mainten therapi character continu treatment particular diseas modifi therapi dmt return diseas activ drug discontinu anoth approach character short treatment cours dmt hypothes act immun reconstitut therapi irt potenti protect relaps year short cours treatment introduct monoclon antibodi treatment ms revolution ms treatment last decad howev given increas complex landscap dmts approv ms peopl ms neurologist constant face question dmt appropri given patient question still answer product review discuss first dmt act irt anti cd monoclon antibodi alemtuzumab anti cd monoclon antibodi ocrelizumab potenti act irt administ continu special emphasi given safeti context covid pandem vaccin strategi | D000086382;D009103;D020529 | T047;T067 |
34,668,841 | eat experi qualiti life patient larynx cancer spain qualit studi paper aim describ eat experi peopl diagnos treat laryng cancer go beyond mere conceptu effect quantif diseas impact basi standard questionnair present qualit analysi narrat experi | D007822;D011788 | T191;T078 |
34,668,839 | influenc footwear foot strike pattern step frequenc spatiotempor paramet lower bodi stiff run studi aim determin influenc footwear condit foot strike pattern step frequenc run spatiotempor paramet lower bodi stiff treadmil run thirti one amateur endur runner perform two session protocol shod barefoot session consist two trial km h minut alter step frequenc everi minut spm first particip instruct land heel first complet protocol repeat land forefoot first repeat measur anova show signific differ footwear condit foot strike pattern step frequenc variabl percent contact time percent flight time vertic stiff leg stiff p result demonstr greater estim vertic leg stiff run barefoot foot strike pattern show largest valu barefootforefoot condit likewis vertic leg stiff becam greater step frequenc increas proper manipul variabl facilit understand run perform assist train programm design injuri manag | D005684;D012420 | T033;T056 |
34,668,837 | involv medic student plan deliveri vaccin health screen outreach clinic improv access healthcar peopl experienc homeless achiev via outreach clinic involv medic student homeless healthcar project lead increas understand social determin health posit chang student percept vulner patient group project increas social account medic school potenti posit effect health local communiti third year medic student gp placement given opportun design deliv temporari clinic homeless popul corbi support public health northamptonshir studi aim evalu educ intervent explor student motiv experi idea sustain project via focus group humanitarian opportun meet patient face face pandem motiv factor join project student felt educ experi valuabl provid exposur patient group often encount medic school gain understand challeng face popul said project forc address unconsci bias cite reason project like mandatori learn experi made student consid fund organis healthcar studi found hand learn provid educ reward experi medic student posit experi gp set may impact career choic allow consid leadership public health | D004504;D013337 | T097;T065 |
34,668,835 | spanish societi hematolog hemotherapi expert consensus opinion sar cov vaccin onco hematolog patient midst covid pandem differ vaccin front sar cov approv administ differ vulner popul patient cancer exclud pivot trial vaccin littl known immunogen respons vaccin particular patient sever impair immun system respons uncertainti spanish societi hematolog hemotherapi launch initi aim provid recommend vaccin main hematolog condit document base avail inform covid outcom prior knowledg vaccin hematolog patient recent publish data serolog respons oncohematolog patient expert opinion new inform sar cov vaccin gather near futur provid new scientif ground delin adequ manag vaccin patient hematolog diseas current limit data sar cov vaccin hematolog patient repres major limit expert consensus opinion fact speed field evolv may reduc valid near futur | D000086382;D006405 | T091;T047;T067 |
34,668,834 | assess plasminogen activ inhibitor pai thrombin activit fibrinolysi inhibitor tafi egyptian children hemophilia patient hemophilia display vari bleed phenotyp correl degre defici factor viii level investig plasminogen activ inhibitor pai level thrombin activat fibrinolysi inhibitor tafi also known carboxypeptidas b cpb level patient hemophilia possibl correl bleed tendenc twenti six patient attend hematolog unit pediatr depart includ studi addit fourteen appar healthi subject match age gender includ control group intern societi thrombosi bleed assess tool isthbat use assess bleed score patient plasma level plasminogen activ fibrinolysi inhibitor pai thrombin activat fibrinolysi inhibitor tafi zymogen measur enzym link immunosorb assay eliza compar control hemophil patient signific high bleed score low pai level high tafi level signific correl bleed score isthbat patient sever pai tafi level signific correl patient sever pai level statist signific differ intens non intens hemorrhag group tafi level signific correl bleed phenotyp pai tafi level signific correl patient control pai level statist signific correl bleed phenotyp tafi level fail show correl intens non intens hemorrhag group pai level may predict valu bleed tendenc hemophiliac | D025901;D006467;D013927 | T116;T047;T126;T046 |
34,668,833 | proteus syndrom case report anatomopatholog correl background proteus syndrom character progress segment patchi growth bone skin adipos tissu central nervous system associ wide rang neoplasm pulmonari patholog thrombot risk main histolog find diffus patchi overgrowth skin subcutan tissu plantar cerebriform connect tissu nevus ossif defect case report present patient met clinic histolog criteria necessari diagnosi diseas requir multipl surgic intervent includ amput right foot genet evalu confirm akt mutat discuss clove syndrom neurofibromatosi pten hamartoma tumor syndrom partial superimpos entiti proteus syndrom may generat diagnost doubt although clinic criteria histolog find indic diagnost confirm entiti genet | D008067;D009139;D009506;D016715;D012878 | T191;T047;T019 |
34,668,831 | phytotoxin produc didymella glomerata truncatella angustata associ grapevin trunk diseas gtds iran didymella glomerata truncatella angustata associ grapevin trunk diseas gtds iran grown vitro evalu product phytotox metabolit potenti pathogen determin dihydroxymethylfuran hydroxyramulosin isol cultur filtrat glomerata angustata respect identifi physic spectroscop essenti h c nmr esim method x ray analysi compound induc signific necrosi curl leav host plant viti vinifera l effect concentr depend effect observ leav non host solanum lycopersicum l plant | D001203;D027843 | T116;T002;T004;T129;T168 |
34,668,830 | fish intak dietari polyunsatur fatti acid lung cancer systemat review dose respons meta analysi million men women determin associ fish intak dietari polyunsatur fatti acid pufa incid lung cancer systemat review meta analyz avail studi quantifi associ fish pufa consumpt risk lung cancer relat risk rr confid interv ci calcul popul base prospect cohort studi involv particip two random control trial includ studi demonstr dietari pufa signific reduc risk lung cancer men rr ci us popul rr ci dose respons analysi indic gday increment dietari pufa associ lower risk lung cancer rr ci addit pufa supplement signific improv overal surviv patient lung cancer rr ci studi show invers associ dietari pufa risk lung cancer male among us popul although smoke cessat singl biggest factor associ lung cancer risk reduct studi add grow bodi evid diet may role modest reduc lung cancer risk | D015525;D008175 | T191;T121;T109;T123 |
34,668,826 | high power q switch nm nm nd yag laser tattoo remov systemat review q switch nm nm nd yag laser present import characterist contribut toward remov tattoo abil reach specif target minim damag tissu despit report clinic benefit scientif studi demonstr efficaci safeti type laser short long term substanti effect benefit safeti applic q switch nm nm nd yag laser systemat review carri septemb decemb studi report use remov tattoo publish last year random clinic trial human consid long evalu efficaci safeti benefit applic q switch nm nm nd yag laser remov black color tattoo differ skin phototyp one hundr twenti two articl identifi titl abstract read duplic remov six articl left includ research individu q switch nm nm nd yag laser seem promis short term minim advers effect howev efficaci safeti long term still present limit consequ futur research necessari better methodolog standard appli follow longer period evalu possibl perman advers effect determin standard safeti therapi laser nd yag de nm nm q switch | D053685;D053844;D013653 | T073;T074;T061;T058;T033 |
34,668,825 | abdomin lymphadenopathi children gaucher diseas relat diseas sever glucosylsphingosin case report seri report abdomin lymphadenopathi aln peopl gaucher diseas gd howev preval among gaucher popul clinic implic potenti biomark unknown henc studi aim assess preval aln among children gd correl neutrophil lymphocyt ratio nlr platelet lymphocyt ratio plr glucosylsphingosin lyso gl fifti children gd type type enzym replac therapi ert compar match healthi control focus histori pressur manifest aln diarrhea constip abdomin pain intestin obstruct histori splenectomi calcul sever score index ssi nlr plr lyso gl measur abdomin ultrasound done assess liver spleen volum aln ct scan done signific lymphadenopathi twenti six children gd aln common present abdomin pain constip intestin obstruct children children gd signific higher nlr p decreas plr p compar control interest children gd aln signific higher ssi lyso gl p nlr p without aln multivari logist regress show aln independ relat lyso gl p nlr p ssi p thus aln preval gd morbid wide clinic spectrum rang asymptomat case intestin obstruct aln relat ssi nlr lyso gl children gdhighlightschildren gd signific higher nlr lower plr compar controlschildren gd aln signific higher ssi lyso gl nlr without alnaln independ relat lyso gl nlr ssi children gd | D005776;D007415;D000072281 | T047 |
34,668,823 | glut target hypoxia activ polym drug conjug base micell tumor chemo thermal therapi mitochondria close correl prolifer metastasi tumor provid suitabl micro environ energi suppli herein construct glucos transport glut target hypoxia activ polyprodrug base micell glu peg azo ir ptx mitochondria specif drug deliveri tumor chemo thermal therapi | D008823 | T109 |
34,668,822 | influenc hydrotrop solubl bioavail curcumin complex format solid state character studi meglumin meg arginin arg act hydrotrop use form stabl curcumin cur hydrotrop complex respect base singl factor experi optim cur megor cur arg complex prepar character fourier transform infrar spectroscopi ftir x ray powder diffract xrd differenti scan calorimetri dsc result show cur megarg complex bound togeth hydrogen bondsor ionic bond success prepar amorph state cur appear complex compar cur meg complex cur arg better stabil stress test cur megarg complex faster drug releas rate vitro area curv auc cur megarg solut rat least fold larger cur suspens find suggest hydrotropi combin solid dispers techniqu simpl effect way improv bioavail curhighlightsth optim cur megor cur arg complex powder prepar characterizedth cur releas rate vitro signific improvedth bioavail improv use cur megor cur arg complexa simpl effect way improv bioavail cur | D003474 | T130;T121;T109 |
34,668,821 | parp inhibitor clinic relev role multidisciplinari cancer team drug safeti cancer consid one devast caus death human innov target therapi becom urgent treatment larg subset diseas last decad develop parp poli adp ribos polymeras inhibitor emerg new target cancer therapi | D009369;D010051 | T191 |
34,668,820 | elucid factor influenc machin learn algorithm predict spastic assess prospect observ studi machin learn model mlm garner popular rehabilit rang develop algorithm outcom predict prognost train artifici intellig high qualiti data play critic role algorithm develop limit studi explor factor may influenc mlm algorithm perform predict spastic sever level object studi train valid mlm algorithm spastic assess determin algorithm predict perform predict ambigu spastic dataset forti seven person central nervous system patholog fulfil inclus exclus criteria recruit four biomechan properti spastic obtain use shelf wearabl sensor data analyz individu ambigu dataset separ accept inerti data use train valid mlm predict spastic train valid mlm algorithm later deploy predict ambigu spastic dataset seri mlm appli includ support vector machin decis tree random forest mlm perform accuraci valid data respect valid mlm accuraci perform level predict ambigu dataset reduc respect studi elucid data bias varianc diseas background pathophysiolog anatom factor consid mlm train | D001185;D000069550 | T066;T073;T090 |
34,668,819 | predictor five year readmiss inpati servic among patient alcohol use disord report low middl incom countri alcohol use disord aud relaps remit diseas account sizabl proport caus adult inpati stay | D000437 | T048 |
34,668,817 | signific reduc loss bone miner densiti four vs six cycl r chop analysi flyer trial patient diffus larg b cell lymphoma dlbcl treat r chop regim receiv high cumul dose prednison use comput tomographi ascertain hounsfield unit hu surrog paramet bone miner densiti bmd three differ locat l vertebr bodi baselin post treatment hu measur patient dlbcl previous publish flyer trial compar four cycl r chop rituximab infus six cycl r chop young favor dlbcl patient total median loss hu patient time median hu loss signific lower four cycl arm hu vs hu p conclus young patient dlbcl receiv r chop signific hubmd loss treatment r chop patient receiv four cycl r chop less hubmd loss patient receiv six cycl | D015519;D016403 | T081;T191;T201 |
34,668,815 | divers outcom extra cranial rhabdoid tumor singl institut experi rhabdoid tumor rts rare aggress pediatr cancer common present alter tumor suppressor gene smarcb howev rt prognosi still poor standard treatment avail moreov predict biomark identifi determin aggress chemo radio sensit herein four case extra cranial rts ert describ two long term survivor two surviv patient posit p wherea two p negat find suggest biolog distinct type ert exist p express may potenti posit prognost biomark ert nevertheless studi requir confirm find | D018335 | T191 |
34,668,814 | nanoliposom drug deliveri system safeti concern review highlight safeti issu drug deliveri system base liposom due small size nm sometim even smaller phospholipid nanoparticl interact intens live system parenter administr interact signific affect transport role safeti therefor special attent paid issu review summaris data basic factor affect safeti nanoliposom composit size surfac charg stabil releas incorpor drug penetr tissu interact complement system attent paid author research uniqu phospholipid nanoparticl diamet nm influenc technolog process nanoliposom product properti consid articl also discuss modern safeti assess criteria contain preliminari regulatori document manufactur countri new nanoliposom base drug develop use clinic | D008081;D053758 | T073;T109 |
34,668,813 | impact color self rate skin tone predict self esteem among women pakistan discrimin complic multifacet long last problem prevail social even polit structur subcontin discrimin basi skin color color make live women miser alreadi victim various dispar color found predictor mental physic health studi intend examin impact color self esteem pakistani women along find determin self esteem cross section studi pakistani femal year rural area conduct studi compris demograph skin relat question everyday discrimin scale rosenberg self esteem scale hierarch linear regress show resid educ color signific predictor p valu self esteem self rate skin tone moder effect color self esteem r chang emphas educ femal special focus suburban area along particip public health dermatologist discourag color stay confid skin tone | D012649;D012880 | T042;T041 |
34,668,812 | reproduct factor breast arteri calcif systemat review meta analysi breast arteri calcif bac common incident find screen mammographi recent evid suggest bac associ cardiovascular diseas cvd systemat review associ bac reproduct factor menopaus status hormon replac therapi hrt use oral contracept oc use pariti | D001941;D001943 | T191;T047 |
34,668,810 | lipid droplet divers function inflamm immun respons lipid droplet lds dynam evolutionari conserv lipid enrich organell compos core neutral lipid surround monolay phospholipid associ divers array protein cell stimulus regul far beyond simpli deposit neutral lipid accumul evid demonstr lds act spatial tempor local lipid protein compartment signal organ | D066292;D050356 | T044;T026 |
34,668,809 | covid season influenza compar analysi patient hematolog malign sever mortal covid season influenza recent compar general popul patient hematolog malign analyz clinic cours patient hematolog malign diagnosi either sar cov n influenza b infect n admit alreadi treatment depart oncolog hematolog stem cell transplant univers medic center hamburg eppendorf germani januari januari covid observ signific higher rate acut respiratori distress syndrom compar influenza group p well signific higher virus associ day mortal vs p base result conclud infect sar cov sever influenza b patient hematolog malign | D000086382;D019337;D007251 | T191;T047;T067 |
34,668,807 | longitudin trajectori associ qualiti life depress among peopl live hiv china mix effect model abstract although depress associ low qol limit research quantifi chang depress improv qol among nave plhiv use art shanghai china studi examin associ depress symptom qol among chines plwh six month longitudin studi data collect peopl live hiv baselin rd month th month initi art use whoqol hiv bref center epidemiolog studi depress scale ces analyz use mix effect model qol improv initi art symptom depress decreas signific depress symptom strong negat associ qol domain qol strength associ decreas time six month follow art differ impact depress symptom qol besid depress symptom strong negat associ qol among plhiv time mental health practition nurs consid art time factor design intervent improv qol target depress symptom intervent design improv qol depress symptom develop target art self manag among plhiv | D015658;D011788 | T047;T078 |
34,668,806 | german pharmaceut price lesson unit state control pharmaceut spend improv access unit state could adopt strategi similar introduc germani german pharmaceut market reorgan act germani manufactur sell new drug immedi upon receiv market approv first year german feder joint committe assess new drug determin ad medic benefit assign score indic ad benefit new drug compar drug refer price group assign group receiv reimburs unless therapeut superior nation associ statutori health insur fund negoti manufactur maximum reimburs start th month consist drug ad benefit assess price cap european countri absenc agreement arbitr board set price manufactur accept price resolut exit market thereaft price general increas even inflat us public privat insur control price divers way typic obtain discount design certain drug prefer restrict patient access charg high copay nonpref drug articl draw lesson drug price reform us feder program privat insur | D016527;D004364 | T121;T081 |
34,668,805 | comparison intraves adjuv therapi bladder cancer two differ mainten regimen mitomycin bcg compar recurr rate side effect two differ mainten regimen postop intraves therapi mitomycin bcg bladder cancer | D001749 | T191 |
34,668,804 | variabl among onlin opioid convers calcul perform common palliat care convers introduct onlin opioid convers calcul oocc common use aid convers opioid overcom toler reduc advers effect challeng relat administr purpos studi describ character variabl among oocc use health care practition convert common opioid dose encount hospic palliat care set method collect quantit survey perform sentiment analysi qualit respons adult learner primarili practic palliat care set enrol onlin palliat care master scienc program univers maryland baltimor ask perform opioid convers calcul use realist patient case result oocc substanti variabl lead wide rang output may put patient risk opioid relat harm assess particip sentiment toward oocc show particip held negat sentiment toward calcul activ conclus overal find reveal given inform clinician come wide differ opioid dose differ amplifi oocc differ particular danger given higher opioid dose common use palliat care set consid signific harm aris error convert opioid clinician avoid routin use oocc real world patient care set oocc use organ endors specif calcul provid train educ algorithm support calcul encourag clinician use manual calcul document medic record | D064420;D017051;D064946 | T046;T091;T093;T037;T058 |
34,668,803 | patient priorit manag covid pandem coronavirus diseas covid pandem affect healthcar system major way general healthcar organ resourc manpow establish manag protocol specif patient pathway evolv continu chang situat neuro vascular manag organ part global measur cope pandem way establish less riski patient pathway help patient triag protect staff introduc train appli safeti measur manag neuro vascular emerg elect activ describ situat pandem affect neuro vascular intervent propos recommend patient triag resourc manag organ remot solut prepar futur wave | D000086382;D058873 | T047;T067 |
34,668,801 | associ hiv test consent polici among sexual activ adolesc differ sexual behavior hiv incid remain high among us youth especi among sexual minor youth howev half youth hiv awar status one potenti explan low hiv test rate restrict polici may prevent minor access hiv test due parent consent requir use pool data local youth risk behavior survey assess whether state hiv test law includ age restrict explicit inclus hiv sti test consent law associ differ hiv test rate differ sexual behavior also examin among femal youth polici associ hiv test howev among male youth presenc age restrict explicit inclus sti servic signific associ increas odd hiv test result indic polici chang may effect increas test among male youth sex male | D015658;D012749 | T047 |
34,668,799 | deep learn base real time tourist spot detect recognit mechan inform tourist spot repres pictur rather text consequ tourist interest specif attract shown pictur may idea perform text search get inform interest tourist spot view problem enhanc competit tourism market research propos innov tourist spot identif mechan base deep learn base object detect technolog real time detect identif tourist spot take pictur locat retriev imag internet research establish tourist spot recognit system look version model built tensorflow ai framework use identifi tourist attract take pictur smartphon camera verifi possibl set tourist spot hsinchu citi taiwan taken exampl current tourist spot recognit system research identifi tourist spot hsinchu addit attract recognit featur tourist use tourist spot recognit system obtain inform tourist spot hsinchu citi govern inform open data platform make dynam travel itinerari plan googl map navig compar deep learn model use faster region convolut neural network singl shot multibox detector algorithm data set recognit time model use look version faster region convolut neural network singl shot multibox detector algorithm respect mean averag precis iou respect perform experiment result research show model use look version algorithm effici precis model use faster region convolut neural network singl shot multibox detector algorithm look version singl shot multibox detector one stage learn architectur effici featur faster region convolut neural network two stage learn architectur precis featur | D000077321 | T066 |
34,668,798 | assess chang symptom feasibl prognost last week life intern multicent cohort studi background symptom typic part establish various prognost factor score system among frequent assess issu patient care object evalu chang symptom provid addit use prognost inform design secondari analysi intern cohort studi japan korea taiwan settingsubject subject adult patient advanc cancer n admit palliat care unit pcus countri januari septemb measur symptom dyspnea fatigu dri mouth drowsi assess admiss one week later dyspnea assess presenc rest exert dyspnea wherea symptom assess use integr palliat care outcom scale ipo rang analysi group patient symptom chang either improv stabl worsen least one increment decreas chang least one increment increas respect result worsen group shortest surviv median surviv day compar improv median surviv day stabl symptom median surviv day across four symptom dyspnea fatigu dri mouth drowsi surviv differ statist signific differ across three group symptom p interest improv symptom associ similar surviv compar stabl group statist differ conclus worsen symptom one week admiss use predictor surviv patient advanc cancer pcus final week life longitudin assess need reflect passag time well impact treatment | D009369;D010166 | T191;T061 |
34,668,795 | elimin opioid anterior cruciat ligament reconstruct prospect random control trial multimod pain protocol effect postsurg pain control howev publish protocol effect elimin opioid consumpt | D018712;D059549 | T121;T061 |
34,668,794 | covid south african experi coronavirus diseas pandem affect countri differ south africa middl incom countri struggl economi resourc constrain public healthcar system three aspect pandem south africa examin lockdown effect person freedom health care resourc use novel stratif health worker vulner categori perspect written experienc first pandem peak | D000086382 | T047;T067 |
34,668,792 | use messag principl design facebook ad promot public engag serious ill care nation healthcar decis day public hesit engag advanc care plan consult palliat care admiss hospic signific barrier improv patient outcom previous studi deriv five empir support messag principl project use messag principl design place analyz second video oregon coalit live well serious ill video script emphas singl messag emerg empir research say care deliber use term advanc care plan prior focus group show consum use term market plan result video facebook includ paid sponsorship full length video facebook boost post three second ad featur key line video test differ elabor central messag facebook analyt indic second video view time week promot three second ad show select moment full length video view total time three second ad one emphas matter near famili click strong outperform nt want go machin heard mani medic horror stori messag combin messag persuad viewer click ad websit use messag principl guid design market facebook ad show public interest serious ill care target social media use reach defin public audienc public messag strategi implement relat low cost | D061108 | T170 |
34,668,791 | social support need hiv posit individu reenter communiti set correct facil johannesburg south africa social network social support import factor medic adher among peopl live hiv plwh social network provid emot logist materi support lead increas overal engag care certain popul plwh may limit access social support includ reenter communiti set correct facil period incarcer social connect famili friend may fray reduc lost studi conduct south africa explor role social support communiti reentri among plwh releas correct facil conduct depth interview communiti reentrant live hiv qualit analysi identifi challeng establish social support reentri greater need social support remain engag hiv care communiti compar correct facil find highlight challeng communiti reentri import social support individu | D015658 | T047 |
34,668,789 | region differ anterior cruciat ligament signal intens surgic treatment magnet reson base measur signal intens use track heal surgic treat anterior cruciat ligament acl howev unknown signal intens valu differ region ligament graft chang heal | D000070598;D059549 | T061;T037 |
34,668,786 | orthoped implant associ central venous cathet associ infect caus microbacterium spp veteran affair healthcar system background year old male develop late onset infect intern fixat devic caus microbacterium oxydan although often consid contamin bacteria genus microbacterium may also pathogen also summar case veteran health administr vha microbacterium isol recov review relev literatur patient method use nation vha databas identifi patient cultur grew microbacterium spp also review publish clinic report describ microbacterium spp caus infect result januari septemb case microbacterium spp microbacterium isol regard pathogen seven case involv prosthet materi consequ remov two patient intern fixat devic wherea remain five patient central venous cathet conclus patient prosthet materi recoveri microbacterium spp devic relat clinic cultur prompt consider devic remov possibl | D055499;D062905;D014728 | T074;T046;T098 |
34,668,782 | six month glycem control hybrid close loop system type diabet patient latin american countri goal studi assess month effect hybrid close loop glycem control type diabet td patient latin america exploratori analysi data prospect collect non select consecut patient td initi treatment minim g system argentina conduct baselin follow visit day carri data download visit total patient age rang year femal n previous use sensor augment pump predict low glucos manag sap plgm baselin glycat hemoglobin includ time rang mgdl signific increas baselin day respect time rang mgdl signific decreas p time rang time virtual train success complet net promot score nps analysi confirm minim g system use allow success achiev glycem control within recommend target non select latin american patient popul underw virtual system train | D003922 | T047 |
34,668,781 | interferon alpha interferon beta act earli control chronic chikungunya virus pathogenesi chikungunya virus chikv arthritogen alphavirus caus debilit acut chronic diseas previous work shown type interferon ifn play critic role limit chikv pathogenesi interferon alpha ifn interferon beta ifn control acut chikv infect distinct mechan howev role type ifn especi specif subtyp chronic chikv diseas unclear address gap knowledg evalu chronic chikv pathogenesi mice lack ifn ifn found ifn domin subtyp control chronic diseas despit detect vari type ifn respons throughout cours diseas ifn act within first day infect control level persist chikv rna addit use novel chikv cre tdtomato report system fate map chikv infect cell show ifn limit number cell surviv chikv site dissemin particular dermal fibroblast immun cell though myofib play signific role chikv diseas impact loss ifn studi highlight ifn ifn play diverg role chronic chikv diseas event occur earli infect cell type equal depend type ifn restrict viral persist import chikungunya virus chikv reemerg global pathogen effect vaccin antivir treatment acut chronic diseas mechan under chronic diseas manifest remain poor defin signific research defin ifn ifn import host regul chronic chikv pathogenesi act within first hour infect limit persist viral rna number cell surviv chikv infect month post infect loss ifn greater impact immun cell dermal fibroblast myofib highlight need delin cell specif respons type ifn altogeth work demonstr earli event acut chikv infect influenc chronic diseas continu effort delin earli host pathogen interact may help stratifi patient risk develop chronic chikv symptom identifi therapeut may prevent progress chronic diseas altogeth | D054884 | T040 |
34,668,779 | viral cellular factor lead loss cd homeostasi hiv virem nonprogressor human immunodefici virus type hiv virem nonprogressor vnps repres rare hiv extrem phenotyp vnps character persist high plasma viremia mainten cd cell count absenc treatment howev caus nonpathogen hiv infect vnps remain elus identifi first time two vnps experienc loss cd homeostasi loh year character deep detail viral host factor associ loh compar standard vnps healthi control viral factor determin includ hiv coreceptor usag replic capac chang cd cd cell activ matur phenotyp express ccr cxcr cd cell also evalu host relat factor consist determin switch hiv coreceptor use cxcr concomit increas replic capac loh two vnps moreov delin increas frequenc hla drcd cd cd cell trace augment naiv cell upon polyclon activ loh remark low stabl level ccr cxcr express cd cell measur time overal result demonstr hiv evolut toward high pathogen cxcr strain context limit stabl express ccr cxcr cd cell potenti driver loh vnps data bring novel insight correl nonpathogen hiv infect import mechan behind nonpathogen human immunodefici virus type hiv infect remain poor understood main low frequenc virem nonprogressor vnps report two case vnps experienc loss cd cell homeostasi loh year hiv infect deep character viral host factor support contribut viral host factor loh vnps thus hiv evolut toward high replic cxcr strain togeth chang cell activ matur phenotyp found moreov measur low stabl level ccr cxcr cd cell time find support viral evolut toward x strain limit coreceptor express control hiv pathogenesi demonstr potenti host depend factor yet fulli elucid vnps control hiv pathogenesi | D018791;D054884;D019562 | T040;T033;T059;T081 |
34,668,777 | opposit effect apoptot necroptot cellular pathway rotavirus replic group rotavirus rva one lead pathogen caus sever acut gastroenter children wide varieti young anim worldwid induc apoptosi upon infect cell though rva induc apoptosi mediat via dual modul nsp nsp protein relat well studi natur signal pathway involv rva induc necroptosi yet fulli elucid demonstr natur rva induc necroptosi signal cascad involv correl rva induc apoptosi infect bovin ncdv human ds rva strain shown activ receptor interact protein kinas ripk ripk mix lineag kinas domain like protein mlkl key necroptosi molecul virus infect cell use immunoprecipit assay ripk found bind phosphoryl ripk pripk pmlkl pmlkl major execution molecul necroptot pathway transloc plasma membran rva infect cell punctur cell membran interest transfect rva nsp also induc necroptosi ripkripkmlkl necroptosi pathway blockag key necroptosi molecul rva infect nsp transfect cell result decreas necroptosi increas cell viabil apoptosi therebi result decreas viral yield rva infect cell contrast suppress rva induc apoptosi increas necroptosi virus yield find suggest rva nsp also induc necroptosi via ripkripkmlkl necroptosi pathway moreov necroptosi apoptosi provir antivir effect respect exhibit cross talk rva infect cell find signific increas understand natur rva induc necroptosi cross talk rva induc necroptosi apoptosi import viral infect usual culmin cell death apoptosi necroptosi rare pyroptosi necroptosi form program necrosi mediat signal complex receptor interact protein kinas ripk ripk mix lineag kinas domain like protein mlkl although apoptosi induct rotavirus nsp protein well known rotavirus induc necroptosi fulli understood demonstr rotavirus also nsp protein induc necroptosi cultur cell activ ripkripkmlkl necroptosi pathway moreov rotavirus induc necroptosi apoptosi opposit effect viral yield ie function provir antivir process respect counterbal rotavirus infect cell find provid import insight understand natur rotavirus induc necroptosi develop novel therapeut strategi infect rotavirus rna virus | D017209;D054884;D000079302;D015398;D014779 | T044;T116;T123;T043;T040 |
34,668,776 | hiv matrix protein p cross blood brain barrier human immunodefici virus type hiv associ neurocognit disord hand remain import neurolog manifest hiv infect hiv patient furthermor detect hiv matrix protein p p central nervous system cns abil form toxic assembl brain recent confirm show first time use vitro blood brain barrier bbb model vivo biodistribut studi healthi mice p cross bbb rapid brain uptak inject activ per gram tissu iag min administr follow brain accumul iag h interact p chemokin receptor cxcr surfac brain endotheli cell trigger transcytosi present studi support hypothesi direct role free p neuron dysfunct hand demonstr intrins abil reach cns import percentag patient affect hiv associ neurocognit disord hand rang hiv infect hiv patient mechan lead hand develop need elucid role secret viral protein chemokin proinflammatori molecul appear clear particular blood brain barrier bbb repres rout entri central nervous system cns thus play import role hand sever find suggest key role hiv matrix protein p p microenvironment factor capabl induc neurocognit disord show abil p cross bbb reach cns thus play crucial role neuron dysfunct hand | D054884 | T040 |
34,668,775 | k human ace transgen mous model recapitul non sever sever covid respons infecti dose sar cov virus comprehens analysi character sever acut respiratori syndrom coronavirus sar cov infect model mimic non sever sever coronavirus diseas covid human warrant underst virus develop prevent therapeut agent character k hace mous model express human h ace mice control human keratin k promot epithelia includ airway epitheli cell sar cov infect typic start found intranas inocul higher viral dose pfu sar cov caus lethal mice sever damag various organ includ lung liver kidney lower dose pfu led less sever tissu damag mice recov infect hace mous model sar cov infect damag multipl tissu dose depend effect tissu similar damag observ postmortem sampl covid patient final mice recov infect low dose virus surviv rechalleng high dose virus compar exist model k hace model seem sensit covid model report date work expand inform avail model includ analysi multipl infecti dose various tissu comparison human postmortem sampl covid patient conclus k hace mous model recapitul sever non sever covid human dose depend provid insight diseas progress efficaci therapeut prevent treat covid import pandem coronavirus diseas covid reach near million case caus near million death worldwid octob rais urgent need develop novel drug therapeut prevent spread pathogenesi sever acut respiratori syndrom coronavirus sar cov achiev goal anim model recapitul featur human covid diseas progress pathogenesi great need studi comprehens character mous model sar cov infect use k hace transgen mice infect mice low high dose sar cov studi pathogenesi surviv respons differ infect pattern moreov compar pathogenesi k hace transgen mice covid patient show model could use tool develop antivir drug therapeut | D004195 | T050 |
34,668,772 | delet el putat diva target pandem strain african swine fever virus produc reduct virul protect virul challeng african swine fever asf current caus major pandem affect swine industri protein avail central europ east south asia commerci vaccin avail make diseas control depend elimin affect anim show delet african swine fever virus asfv el gene high virul asfv georgia asfv g isol produc reduct virus virul infect swine domest pig intramuscular inocul recombin virus lack el gene asfv g el experienc signific day delay present clinic diseas overal rate surviv compar anim inocul virul parent asfv g import anim surviv asfv g el infect develop strong antibodi respons protect challeng asfv g expect pool sera asfv g el inocul anim lack detect antibodi respons peptid partial repres el protein sera anim inocul efficaci vaccin candid asfv g mgf strong recogn set peptid result support potenti use el delet develop vaccin abl differenti infect vaccin anim diva therefor shown el gene novel asfv determin virul potenti use increas safeti preexist vaccin candid well provid diva capabl knowledg el first asfv gene product experiment shown function diva antigen marker import commerci vaccin avail prevent african swine fever asf asf pandem caus asf virus georgia asfv g strain serious affect pork product contigu geograph area central europ east asia effect experiment vaccin virus attenu delet asfv gene associ virus virul therefor identif gene critic import vaccin develop report discoveri novel determin asfv virul el gene delet el gene asfv g genom asfv g el produc reduct virus virul import anim surviv infect asfv g el protect develop asf challeng virul parent virus asfv g import virus protein encod el high immunogen make virus lack gene vaccin candid allow differenti infect vaccin anim diva show unlik observ anim inocul vaccin candid asfv g mgf asfv g el inocul anim mount el specif antibodi respons indic feasibl use el delet antigen marker develop diva vaccin asfv | D054884;D017384 | T040;T049 |
34,668,770 | pharmacolog manag emerg child adolesc psychiatri pharmacolog manag emerg child adolesc psychiatri abstract emerg child adolesc psychiatri high preval often pose signific challeng physician sinc substanti danger patient other must avoid applic larg moder intervent besid use de escal strategi exploit psychotherapeut option physician frequent employ psychopharmacolog intervent lack systemat assess data howev emerg child adolesc psychiatri administr psychotrop drug occur label review deduc practic relev recommend pharmacolog manag occur child adolesc emerg acut suicid acut psychot episod delirium disord conscious acut intox alcohol withdraw syndrom discuss issu qualiti safeti pharmacolog emerg strategi | D000437;D002665;D001523;D013375 | T091;T048;T184 |
34,668,769 | util deep learn algorithm detect reticular opac chest radiographi patient interstiti lung diseas background deep learn heavili explor pulmonari nodul detect chest radiograph detect reticular opac interstiti lung diseas ild challeng may also benefit deep learn algorithm dla object purpos studi evalu util dla detect reticular opac chest radiograph patient surgic confirm ild method retrospect studi includ patient men women mean age sd year surgic proven ild januari decemb underw preoper chest radiographi chest ct within day interv total age sex match control patient normal chest radiograph random select commerci avail dla use detect lower lobe subpleur abnorm match reticular opac locat ct deem true posit six reader three thorac radiologist three resid independ review radiograph without dla presenc reticular opac interobserv agreement assess diagnost perform compar among interpret subanalysi perform accord ct base classif sever reticular opac perform dla also assess chest radiograph second institut patient ild match patient control group result interobserv agreement moder reader alon almost perfect reader use dla sensit specif accuraci dla reticular opac pool reader alon reader use dla metric signific better p dla reader use dla reader alon sensit reader without dla mild diseas moder diseas sever diseas dla accuraci second institut conclus dla outperform reader detect reticular opac use dla improv reader perform interobserv agreement benefit dla notabl sensit specif maintain mild diseas clinic impact use dla may facilit detect reticular opac chest radiograph earli stage ild | D000077321;D017563 | T047;T066 |
34,668,765 | amelior effect myricetin nonalcohol fatti liver diseas obob mice obes insulin resist oxid stress import risk factor nonalcohol fatti liver diseas nafld studi aim determin benefici effect myricetin nafld obob mice cbl lep obob mice n fed g diet obob control group diet contain low myricetin lmtn group high myricetin hmtn group myricetin lean heterozyg litterm lean control group n fed g diet week hmtn consumpt signific lower serum glucos level homeostasi model assess insulin resist valu obob mice addit reduc serum triglycerid tg cholesterol level hmtn signific decreas total hepat lipid tg level part downregul carbohydr respons element bind protein sterol regulatori element bind protein c express reduct level hepat thiobarbitur acid reactiv substanc hmtn like result elev nuclear factor erythroid relat factor express tumor necrosi factor monocyt chemoattract protein express reduc lmtn hmtn hmtn also decreas interleukin express result suggest myricetin benefici effect nafld regul express transcript factor hepat lipid metabol antioxid system pro inflammatori cytokin | D065626 | T047 |
34,668,764 | echinacea purpurea extract enhanc natur killer cell activ vivo upregul mhc ii th type cd cell respons number factor caus immun system disrupt includ infect caus foreign antigen decreas immun due excess exercis public interest improv immun grow studi investig immunomodulatori effect echinacea purpurea e extract cbln mice expos forc swim exercis six experiment group follow wild type forc swim exercis control posit control red ginseng mgkg e mgkg bw group mice administ e extract week detect chicor acid activ substanc e high perform liquid chromatographi evalu chang follow laboratori valu respons forc swim exercis use flow cytometri elisa major histocompat complex mhc cd cd cell th th cytokin natur killer nk cell activ number leukocyt oral e intak increas level mhc ii cd cell th cytokin nk cell activ addit e treatment increas b cell prolifer leukocyt count immunoglobulin level taken togeth result suggest chicor acid e improv immun respons control nk cell activ may use function immunomodul system | D020900 | T002 |
34,668,763 | fucoidan protect high fat diet induc obes modul gut microbiota institut cancer research mice fucoidan possess various biolog activ anticoagul immunomodulatori anti inflammatori potenti antioxid other studi investig effect fucoidan high fat diet induc obes inflamm gut microbiota institut cancer research mice mice gavag mg kgd fuc group mg kgd fuc group fucoidan week fucoidan allevi obes tissu damag decreas bodi weight bodi mass index decreas bodi weight gain improv organ index liver steatosi improv structur small intestin addit fucoidan decreas total cholesterol triglycerid low densiti lipoprotein cholesterol increas high densiti lipoprotein cholesterol moreov fucoidan reduc serum lipopolysaccharid concentr tumor necrosi factor total bile acid furthermor fucoidan improv structur gut microbiota signific increas abund shannon divers index even faecalibacterium prausnitzii determin denatur gradient gel electrophoresi quantit pcr conclus studi provid scientif basi fucoidan function food modul gut microbiota protect obes | D000069196;D009369 | T007;T191;T001 |
34,668,761 | copar problem parent behavior mediat link interparent conflict toddler adjust difficulti germani object interparent conflict long acknowledg major risk factor well children empir studi reveal clear associ children maladjust frequent destruct conflict parent van eldik et al exist research suggest interparent conflict spill coupl coparent relationship undermin parent skill cooper parent compet studi address effect interparent conflict behavior emot problem toddler method analys base longitudin data german famili panel pairfam sampl compris inform n anchor particip femal year old children result expect effect interparent conflict children behavior emot problem mediat copar problem part also negat parent analys compar mother father reveal stronger direct path interparent conflict copar mother conclus find provid support signific interparent relationship copar qualiti child develop even young age group point import earli prevent | D054541;D016487 | T033;T054;T098 |
34,668,758 | real world evid practic toolbox collect health state util health state util hsu data collect real world evid studi risk bias although numer guidanc document avail practic advic avoid bias hsu studi limit thus object articl develop concis toolbox intend investig seek collect hsu real world set propos toolbox build exist guidanc provid practic step help investig perform good qualiti research toolbox aim increas credibl hsu data futur reimburs decis make | D015982 | T078 |
34,668,755 | microbi communiti composit municip wastewat treatment bioreactor follow distanc decay pattern primarili control environment heterogen understand spatiotempor pattern microbi communiti composit central goal microbi ecolog object studi better understand biogeographi activ sludg microbi communiti import protect surfac water qualiti month sampl collect facil bioreactor within km year microbi communiti composit character sequenc pcr amplifi rrna gene fragment statist signific distanc decay communiti similar observ bioreactor independ cluster method oper taxonom unit otus similar genus level phylotyp communiti dissimilar metric srensen bray curti weight unifrac univers colon ie detect sampl ubiquit genus level phylotyp ie detect everi facil least also exhibit signific distanc decay relationship variat partit analysi communiti composit show environment characterist temperatur influent characterist etc explain varianc communiti composit geograph distanc suggest environment heterogen import dispers limit mechan determin microbi communiti composit distanc decay relationship also becam stronger increas distanc facil season variat communiti composit also observ select bioreactor clear season pattern distanc decay relationship import understand spatiotempor pattern biodivers central goal ecolog distanc decay communiti similar one spatial scale pattern observ mani form life includ plant anim microbi communiti municip wastewat treatment reli microorgan prevent releas excess quantiti nutrient pollut relat studi explor distanc decay relationship wastewat treatment bioreactor result demonstr strong distanc decay pattern wastewat treatment bioreactor regardless sequenc cluster method communiti dissimilar metric result suggest microbi communiti wastewat treatment bioreactor random assembl rather exhibit statist signific spatial pattern | D064307 | T032;T001;T028 |
34,668,752 | nontyphoid salmonella food latin america systemat review latin america nontyphoid salmonella nts one import etiolog agent foodborn infect surviv soil water food even process aim perform systemat review collect data preval serotyp antimicrobi resist amr nts isol differ food product latin america follow prefer report item systemat review meta analys guidelin studi screen report latin american countri elig among report nts preval report nts serotyp report serotyp amr pattern nts preval rang regardless countri food meat show highest nts preval enteritidi typhimurium derbi frequent observ serotyp differ food product serotyp enteritidi typhimurium infanti isol anim product show highest amr rate presenc nts fruit veget general consum raw readi eat food indic high risk salmonellosi consum food thus reduct pathogen food chain requir one health approach involv good agricultur manufactur practic low antimicrobi use proper wast manag | D000890;D012478;D012480 | T047;T121;T037 |
34,668,749 | genom character two novel rca phage reveal new insight divers evolut marin virus virus abund live entiti marin ecosystem play critic role alter structur function microbi communiti drive ocean biogeochemistri phage infect roseobact clade affili rca cluster strain import compon marin viral communiti character genom sequenc two new rca phage crp crp infect rca strain fzcc genom analysi reveal crp crp repres novel evolutionari lineag marin phage dna replic modul similar cobavirus group phage contrast morphogenesi packag modul distinct cobavirus homolog hmo type phage genom architectur crp crp suggest genom recombin event distinct phage group metagenom data set examin metagenom assembl viral genom mavg similar recombin genom architectur fifteen crp type mavg identifi marin virom addit mavg identifi contain hmo type morphogenesi packag modul type dna replic gene provid evid recombin differ phage group major driver phage evolut altogeth studi signific expand understand divers evolut marin roseophag meanwhil analysi novel rca phage mavg highlight critic role recombin shape phage divers phage sequenc valuabl resourc infer evolutionari connect distinct phage group import divers evolut phage infect relat slow grow domin roseobact lineag larg unknown studi rca phage crp crp isol roseobact rca strain shown uniqu genom architectur appear result recombin event crp crp dna replic modul similar cobavirus group phage morphogenesi packag modul similar hmo type phage hmo type morphogenesi packag modul found combin distinct type dna replic gene suggest compat various dna replic modul altogeth studi contribut toward better understand marin viral divers evolut | D000083422 | T005 |
34,668,748 | character tonsil microbiota effect adenovirus reactiv tonsillectomi sampl adenovir dna preval adenotonsillectomi specimen pediatr patient though virus seem latent state tonsil forefront airway entri point first line defens airway viral bacteri infect hypothes tonsil microbiota play role human adenovirus hadv latenc reactiv studi survey presenc hadv tonsillectomi sampl patient found hadv dna tonsil sampl determin microbiota sampl taxonom profil show proteobacteria firmicut fusobacteriota bacteroidota account approxim total phyla tonsil sampl correl analysi show hadv posit sampl signific higher abund neisseria bifidobacterium lower abund streptococcus ochrobactrum lactobacillus hadv negat sampl cultur base isol follow rrna sequenc identifi staphylococcus aureus streptococcus pneumonia veillonella prevotella capnocytophaga sputigena pseudomona aeruginosa neisseria moraxella catarrhali sampl gas chromatographi mass spectrometri gc ms profil short chain fatti acid bacteri cultur minc tonsillectomi tissu repres isol show cultur contain various amount short chain fatti acid scfas treatment isol tonsil lymphocyt bacteri lipopolysaccharid lps scfas promot hadv reactiv compound also promot hadv reactiv xenograft model implant tonsil fragment studi show potenti interplay tonsil microbiota hadv reactiv may lead recurr virus infect respiratori tract diseas import human adenovirus infect common among pediatr patient life threaten among organ transplant recipi adenovirus transmit close contact believ major invas event appear aris viral reactiv human tonsil reservoir virus latenc high preval latent infect adenovirus also tonsil locat gateway respiratori tract common expos bacteri pathogen uncov adenovir dna posit negat sampl appear harbor distinct distribut pattern microorgan scfas primari metabolit microbiota tonsil could induc adenovirus reactiv tonsil lymphocyt result adenovirus replic product infecti virion studi suggest viral bacteri interact play role virus reactiv latenc could contribut factor recurr viral infect pediatr patient | D064307 | T032;T001;T028 |
34,668,746 | robust evalu ultraviolet c sensit sar cov surrog coronavirus uv light specif uv c light wavelength nm often use disinfect surfac air liquid earli cusp covid pandem uv light identifi effici mean elimin coronavirus howev variabl publish sensit data evid need experiment rigor accur quantifi effect techniqu current studi reliabl reproduc uv techniqu adopt includ accur measur light intens consider fluid uv absorb confirm uniform dose deliveri includ dose verif use establish biolog target tuv bacteriophag resist recombin virus baculovirus experiment result establish uv sensit sar cov hcov e hcov oc mous hepat virus mhv highlight potenti surrog virus disinfect studi four coronavirus found easili inactiv nm irradi uv sensit mjcm log reduct sar cov hcov e hcov oc mhv respect similar uv sensit speci demonstr capac hcov oc hcov e mhv consid surrog sar cov uv inactiv studi great reduc hazard simplifi procedur futur experiment studi import disinfect sar cov particular import due global covid pandem uv c irradi compel disinfect techniqu appli surfac air water common use drink water wastewat treatment facil uv inactiv depend dose receiv organ regardless intens light sourc optic properti medium suspend nm irradi sensit accur determin use benchmark methodolog collim beam apparatus four coronavirus sar cov hcov e hcov oc mhv surrog indic organ tuv resist recombin virus baculovirus vector consid light distribut across sampl surfac attenu light intens fluid depth optic absorb fluid sampl uniform due mix enabl accur measur fundament inactiv kinet uv sensit | D014466 | T070 |
34,668,743 | repurpos tamoxifen metabolit treat methicillin resist staphylococcus epidermidi vancomycin resist enterococcus faecali infect repurpos drug provid new approach fight multidrug resist mdr bacteria report three major tamoxifen metabolit n desmethyltamoxifen dtam hydroxytamoxifen htam endoxifen endx present bactericid activ acinetobact baumannii escherichia coli aim analyz activ mixtur three tamoxifen metabolit methicillin resist staphylococcus epidermidi mrse enterococcus speci mrse n enterococcus speci enterococcus faecali n enterococcus faecium n strain use mic mixtur dtam htam endx vancomycin determin microdilut assay bactericid activ three metabolit togeth vancomycin mrse se se vancomycin resist e faecali evr evr strain determin time kill curv assay final chang membran permeabl se evr strain analyz use fluoresc assay mic tamoxifen metabolit mgliter mrse strain mgliter e faecali e faecium strain time kill assay tamoxifen metabolit mixtur show bactericid activ mic mrse se se mic mic e faecali evr evr strain respect se evr strain treat tamoxifen metabolit mixtur present higher membran permeabil altogeth result show tamoxifen metabolit present antibacteri activ mrse vancomycin resist e faecali suggest tamoxifen metabolit might increas arsenal drug treatment bacteri pathogen import develop new antimicrobi therapeut strategi requir immedi attent avoid ten million death predict occur result mdr bacteri infect studi assess antibacteri activ three major tamoxifen metabolit n desmethyltamoxifen dtam hydroxytamoxifen htam endoxifen endx methicillin resist staphylococcus epidermidi mrse enterococcus spp e faecali e faecium found tamoxifen metabolit antibacteri activ mrse e faecali e faecium strain present mic mgliter bactericid activ h addit antibacteri activ parallel increas membran permeabl strain result show tamoxifen metabolit might potenti use therapeut altern treat mrse e faecali strain anim model infect | D016106 | T032 |
34,668,740 | use electron cigarett e cig e shisha children adolesc evid paper joint addict commiss german societi profession associ child adolesc psychiatri psychotherapi use electron cigarett e cig e shisha children adolesc evid paper joint addict commiss german societi profession associ child adolesc psychiatri psychotherapi abstract particular risk associ consumpt electron cigarett e cig children adolesc suffici consid health polici discours present articl evalu current dissemin consumpt pattern e cigarett well health risk attach children adolesc base data current nation intern studi clear increas consumpt e cigarett past year stand sharp contrast overal declin tobacco consumpt among children adolesc germani young peopl without tobacco experi consum frequent e cigarett occasion regular use tobacco also experi frequent convent cigarett previous consum e cigarett larg unregul avail e cigarett product newest generat juul led dramat increas preval among high school student usa product high nicotin content multipl flavor market intens trendi lifestyl product young user group via advertis social media campaign product also becom increas relev germani success tobacco prevent recent year present jeopard ongo effect advertis e cigarett addict commiss german child youth psychiatr feder scientif societi therefor call immedi strict comprehens ban e cigarett advertis | D016739;D066300;D000075387 | T048;T073 |
34,668,738 | risk factor seroneg follow sar cov infect larg cohort health care worker denmark individu seroconvert infect sever acut respiratori syndrom coronavirus sar cov seroneg observ aim investig risk factor associ seroneg follow pcr confirm sar cov infect prospect cohort studi screen health care worker hcw capit region denmark sar cov antibodi perform three round screen april octob use enzym link immunosorb assay elisa method target sar cov total antibodi data particip pcr sar cov rna captur nation registri kaplan meier method cox proport hazard model appli investig probabl seroneg relat risk factor respect hcw posit pcr studi period median interquartil rang iqr age hcw year femal median rang day seroneg multivari model independ risk factor seroneg self report asymptomat mild infect hazard ratio hr confid interv ci p bodi mass index bmi hr ci p hcw seroposit asymptomat mild infect well bmi associ seroneg sinc presenc antibodi sar cov reduc risk reinfect effort protect hcw risk factor seroneg may need futur covid surg import individu seroconvert infect sever acut respiratori syndrom coronavirus sar cov negat serolog observ found asymptomat mild infect well bmi associ seroneg sinc presenc antibodi sar cov reduc risk reinfect effort protect hcw risk factor seroneg may need futur covid surg | D000087124 | T059 |
34,668,737 | character first cultur psychrotoler repres legionella antarctica reveal uniqu genom structur cultur independ analysi show legionella spp inhabit wide rang low temperatur environ date psychrotoler psychrophil strain report character first cultiv psychrotoler repres design strain tum isol antarct lake use polyphas approach compar genom analysi genom wide phylogenet tree indic strain phylogenet separ speci level strain tum share common physiolog trait eg gram negat limit growth buffer charcoal yeast extract ketoglutar bcye agar l cystein requir relat also show psychrotoler growth properti eg growth c c moreov strain alter cellular fatti acid composit accumul unsatur fatti acid lower temperatur may help maintain cell membran fluiditi compar genom analysi found strain possess massiv mobil genet element compar speci amount total gene major element result spread insert sequenc iss spread throughout genom copi past mechan furthermor found metabol gene fatti acid synthesi relat gene acquir horizont gene transfer hgt expans iss hgt event may play major role shape phenotyp physiolog strain basi featur present propos new speci legionella antarctica sp nov repres strain tum gtc nctc import studi character uniqu cultiv repres genus legionella isol antarct lake psychrotoler strain common properti known legionella speci also display characterist plastic fatti acid composit enrich mobil gene genom remark properti well factor may contribut cold hardi first cultiv cold toler strain genus legionella may serv model bacterium studi worth note environment deriv rrna gene phylotyp close relat strain character detect divers environ outsid antarctica suggest wide distribut psychrotoler legionella bacteria cultur genom base find may acceler ongo studi behavior pathogen legionella spp monitor mani year context public health | D016680 | T028 |
34,668,735 | beyond standard care exploratori qualit studi implement integr therapeut care program brazilian pediatr oncolog unit introduct articl examin feedback health care provid within implement integr care project clinic pediatr oncolog paulo brazil sinc project implement extern anthroposoph therapi activ daili nurs object evalu project evolv impact daili oper hospit special focus emphas perspect studi nurs materi method twelv qualit semistructur interview conduct audio file transcrib translat german underw maxqda softwar assist analysi use themat approach coher cross case topic defin result three main topic emerg analysi data implement effect daili patient care demonstr posit outcom patient well accept minim chang daili activ perspect studi nurs show larg motiv due benefici stress reliev effect applic grow patient health care provid relationship problem aspir improv lack time urg make project grow futur conclus patient also health care provid seem benefit integr method potenti improv work atmospher strengthen relat patient caregiv famili member general feedback posit accept team aros time benefici effect becam visibl | D000073196;D009369 | T191;T061 |
34,668,734 | intestin bacteriophag therapi look optim efficaci sever human intestin microbiota studi suggest bacteriophag virus infect bacteria play role gut homeostasi current bacteriophag consid tool precis engin intestin microbiota also attract consider attent possibl solut fight bacteri pathogen resist antibiot two applic necessit bacteriophag reach kill bacteri target within gut environ unfortun exploit clinic data field scarc review administr bacteriophag target intestin bacteria mammalian experiment model bacteriophag amplif gut often confirm found studi signific impact load target bacteria particular observ outcom bacteriophag treatment link behavior target bacteria toward anim model treatment efficaci rang poor asymptomat intestin carriag high intestin diseas broad rang efficaci underlin difficulti reach consensus impact bacteriophag gut call deeper investig key paramet influenc success intervent launch clinic trial | D001435;D000069196;D000071059 | T061;T007;T001;T005 |
34,668,733 | compar analysi cultur total bacteri communiti wheat rhizospher microbiom use cultur depend cultur independ approach rhizospher root associ bacteria key compon crop product sustain agricultur howev util benefici bacteria often limit convent cultur techniqu major soil microorgan cultur use standard laboratori media therefor purpos studi improv cultur investig divers bacteri communiti wheat rhizospher microbiom collect three locat egypt contrast soil characterist use metagenom analysi improv cultur base method improv strategi cultur depend approach includ replac agar medium gellan gum modifi prepar autoclav phosphat gell agent separ compar total oper taxonom unit otus observ metagenom data set deriv three analyz soil bacteria recov use modifi cultiv strategi wherea less obtain employ standard cultiv protocol twenti one percent cultiv isol exhibit multipl plant growth promot pgp properti includ p solubil activ siderophor product metagenom analysi abund phyla proteobacteria actinobacteria chloroflexi bacteroidet firmicut moreov relat abund specif bacteri taxa correl soil characterist demonstr effect soil modul plant rhizospher microbiom import bacteria colon rhizospher narrow zone soil surround root system known benefici effect improv growth stress toler plant howev bacteria natur environ especi rhizospher soil recalcitr cultiv use tradit techniqu thus role soil health plant growth remain unexplor henc investig new cultur media cultur condit bring yet cultur speci cultiv identifi new function still import task microbiologist end describ improv cultiv protocol increas number divers cultur bacteria rhizospher wheat plant use approach lead new insight cultur benefici bacteria live plant rhizospher creat greater opportun field applic also promot sustain | D064307;D058441;D012988 | T001;T032;T028;T067;T070 |
34,668,730 | loss major nutrient sens signal pathway suppress starvat lethal electron transport chain mutant electron transport chain etc well studi high conserv metabol pathway produc atp generat proton gradient across inner mitochondri membran coupl oxid phosphoryl etc mutat associ wide array human diseas condit age relat phenotyp number differ organ studi sought better understand role etc age use yeast model panel etc mutant strain fail surviv starvat use isol suppressor mutant surviv suppressor tend fall major nutrient sens signal pathway suggest etc involv proper starvat signal pathway yeast suppressor also partial restor etc associ gene express ph homeostasi defect though remain unclear whether phenotyp direct caus suppress simpli effect work highlight complex cellular network connect metabol pathway signal event cell potenti role age age relat diseas | D009154 | T045 |
34,668,721 | semirapid detect piperacillintazobactam resist extend spectrum resist lactam lactamas inhibitor clinic isol escherichia coli piperacillintazobactam tzp lactam lactamas inhibitor blbli recommend empir treatment sever infect excess indiscrimin use tzp promot emerg tzp resist escherichia coli isol recent demonstr tzp may contribut develop e xtend pectrum r esist blbl esri e coli isol tzp suscept low level resist blbli resist amoxicillinclavulan acid amc andor ampicillinsulbactam sam rais need develop rapid detect system therefor object studi design valid method abl detect tzp resist esri e coli colorimetr assay base lactam ring hydrolysi lactamas design esri test total e coli isol bloodstream intra abdomin sourc character accord suscept profil blbli use detect three frequent lactamas involv blbli resist bla tem bla oxa bla shv perform pcr esri test abl detect tzp intermedi resist isol well tzp suscept isol capac esri develop median time result min respect isol without resist blbli display negat result esri test bla tem frequent lactamas gene detect follow bla shv bla oxa result demonstr efficaci esri test show great clinic potenti could lead reduct health cost ineffect treatment inappropri use blbli import tzp blbli recommend empir treatment sever infect excess use tzp promot emerg tzp resist escherichia coli isol recent report tzp may contribut develop esri e coli isol tzp suscept low level resist blbli rais need develop rapid detect system demonstr esri test abl detect tzp intermedi resist isol tzp suscept isol capac esri develop isol without blbli resist negat esri test harbor lactamas gene esri develop tzp intermedi resist isol bla tem frequent lactamas gene detect follow bla shv bla oxa sensit specif posit negat predict valu data demonstr efficaci esri test show great clinic potenti | D024901 | T032 |
34,668,718 | budesonideformoterol versus salmeterolfluticason asthma children effect safeti analysi background efficaci budesonid formoterol therapi compar high dose salmeterol fluticason therapi plus short act agonist saba evalu specif children object evalu efficaci safeti budesonid formoterol combin therapi two time day plus need compar salmeterol fluticason two time day plus saba need children china method prospect cohort studi includ children persist asthma age year experienc minimum one asthma exacerb month prior studi primari outcom time first sever exacerb result eighti two children assign two group exacerb rate per patient per year found signific differ number patient hospitalizationemerg room therapi lower budesonid formoterol group risk differ statist signific asthma control measur show compar effect treatment well toler conclus signific differ observ outcom measur group budesonid formoterol therapi favor approach term low load ic steroid exposur need multipl inhal cost | D001249;D000068297 | T047;T121;T109 |
34,668,717 | mechan triphosph hydrolysi human mata resolut human methionin adenosyltransferas mata provid adenosyl l methionin adomet methyl transfer reaction epigenet methyl influenc express pattern develop cancer transit state analysi kinet studi describ mechan adomet triphosph format catalyt site hydrolysi triphosph pyrophosph phosphat mata requir product releas proceed second chemic transit state crystal structur mata analogu adomet pyrophosph obtain presenc mg al f mgf trap po mimic structur malon fill pyrophosph site nmr demonstr mgf alf bound mata mimic depart phosphoryl group crystallograph analysi reveal planar mgf act mimic phosphoryl po leav group model transit state po phosphorus atom sandwich symmetr equidist approxim pyrophosph oxygen water nucleophil catalyt site arginin direct nucleophil water phosphoryl leav group catalyt geometri transit state reconstruct predict loos transit state characterist symmetr nucleophil displac | D055162 | T070 |
34,668,716 | develop biodegrad lipid nanoparticl intracellular mrna deliveri genom edit sinc us food drug administr fda grant emerg use author two mrna vaccin sar cov mrna base technolog attract broad attent scientif communiti investor deliv intracellular mrna abil produc various therapeut protein enabl treatment varieti ill includ limit infecti diseas cancer genet diseas accord mrna hold signific therapeut potenti provid promis mean target histor hard treat diseas current clinic effort har mrna base technolog focus vaccin cancer immunotherapi protein replac therapi genom edit clinic translat mrna base technolog made possibl leverag nanoparticl deliveri method howev applic mrna therapeut purpos still challeng need specif effici safe deliveri systemsthi account highlight key advanc design develop combinatori synthet lipid nanoparticl lnps distinct chemic structur properti vitro vivo intracellular mrna deliveri lnps repres advanc nonvir nanoparticl deliveri system extens investig nucleic acid deliveri aforement covid mrna vaccin one lnp base small interf rna sirna drug onpattro receiv clinic approv fda highlight success synthet ioniz lipid vivo nucleic acid deliveri account first summar research effort group develop bioreduc biodegrad lnps leverag combinatori chemistri strategi michael addit reaction allow us easili generat larg set lipidoid divers chemic structur next discuss util librari screen strategi identifi optim lnps target mrna deliveri showcas applic optim lnps cell engin genom edit final outlin key challeng clinic translat mrna base therapi propos outlook futur direct chemic design optim lnps improv safeti specif mrna drug hope account provid insight ration design lnps facilit develop mrna therapeut transform technolog promis revolution futur medicin | D000072669;D018014 | T062;T063 |
34,668,711 | cucurbituril effector self assembl pd ii pt ii metallacycl four bident dication ligand l l prepar investig guest bind cucurbit uril cb host structur compon metal pd pt coordin self assembl metallacycl aqueous solut ligand found form stabl complex variabl stoichiometri cb one l fail self assembl induc presenc suitabl pd pt complex metallacycl exposur pd base metallacycl cb led disassembl room temperatur pt base metallacycl remain stabl condit howev heat pt metallacycl presenc cb also led disassembl interplay interact aqueous media l l l ligand cb host pd pt complex suggest possibl use relat system control drug deliveri applic | D047028 | T109 |
34,668,708 | develop valid amber fb compat forc field paramet phosphoryl amino acid phosphoryl select amino acid residu one common biolog mechan regul protein structur function comput model use explor detail structur chang associ phosphoryl molecular mechan forc field develop simul phosphoprotein note inconsist experiment data work parameter forc field phosphoryl form amino acid serin threonin tyrosin use forcebal softwar packag goal improv agreement experi residu optim forc field denot fb parameter use high qualiti ab initio potenti energi scan design fulli compat amber fb protein forc field util md simul togeth tipp fb water model find fb consist enhanc predict experiment quantiti j nmr coupl intramolecular hydrogen bond propens comparison previous publish model report amber fb also see improv agreement refer qm calcul region away local minima thus believ fb paramet set provid promis rout investig vari effect protein phosphoryl | D000596;D056004 | T044;T116;T121;T066;T123 |
34,668,706 | design two one mutant select epiderm growth factor receptor inhibitor span orthoster alloster site inhibitor target epiderm growth factor receptor egfr effect therapi patient non small cell lung cancer harbor drug sensit activ mutat egfr kinas domain drug resist due treatment acquir mutat motiv develop success generat inhibitor bind atp site third generat agent osimertinib first line treatment diseas recent alloster inhibitor develop overcom drug resist mutat confer resist osimertinib present structur guid design synthesi mutant select lead compound consist pyridinyl imidazol fuse benzylisoindolinedion scaffold simultan occupi orthoster alloster site compound potent inhibit enzymat activ lrtmcs mutant egfr nm signific lower activ wild type egfr nm addit compound achiev modest cetuximab independ mutant select cellular efficaci lr lrtm variant | D015195;D009154 | T090;T045 |
34,668,704 | photochemistri cannabidiol cbd revis combin prepar spectrometr investig cannabi plant astonish abil biosynthes cannabinoid molecul belong class isol among recent year cannabidiol cbd receiv interest pharmacolog major nonpsychotrop cannabinoid mani potenti clinic applic although reactiv cbd wide investig littl attent given possibl photodegrad cannabinoid data avail literatur outdat case conflict aim present work provid character photochem behavior cbd organ solvent detail gc ms analys isol nmr character photoproduct obtain | D010782 | T044;T070 |
34,668,703 | climat justic california methan superemitt environment equiti assess communiti proxim exposur intens methan superemitt emit non methan copollut harm human health yet prior studi assess dispar exposur methan superemitt respect raceethn socioeconom status civic engag obtain locat categori eg landfil refineri emiss rate california methan superemitt next generat airborn visibleinfrar imag spectromet aviri ng flight conduct identifi block group within km superemitt expos km away unexpos use dasymetr map assign level exposur among block group within km measur via number superemitt categori total methan emiss analys includ superemitt major dairymanur n oilga product site n result fulli adjust logist mix model indic environment injustic methan superemitt locat exampl everi increas non hispan black resid odd exposur increas confid interv ci observ similar dispar hispan nativ american indic socioeconom status among block group locat within km increas proport non white popul lower voter turnout associ higher superemitt emiss intens previous unrecogn racialethn dispar exposur california methan superemitt consid polici tackl methan emiss | D008697;D012935 | T080;T109;T078 |
34,668,702 | less order hydrat shell around poli n n diethylacrylamid insensit cloud transit raman multivari curv resolut raman mcr appli examin hydrat shell around poli n n diethylacrylamid pdeam chang upon heat comparison poli n isopropylacrylamid pnipam undergo cloud transit near room temperatur report pdeam possess less order smaller hydrat shell pnipam furthermor pdeam hydrat shell structur insensit occurr cloud indic coil globul transit aggreg multipl chain achiev without hydrat shell structur transform | D011108;D014867 | T104;T122;T121;T197 |
34,668,699 | dynam post translat modif inspir drug design kinas famili post translat modif ptm protein play import role regul cellular function diseas pathogenesi systemat analysi ptm dynam present great opportun enlarg target space ptm alloster regul present framework integr sequenc structur topolog particular dynam featur character function context druggabl ptms well known kinas famili machin learn model biophys featur could success predict ptms hand ptms identifi signific enrich report alloster pocket alloster potenti ptm pocket thus propos biophys featur end coval inhibitor dc srci target ptm pocket c src kinas identifi inhibit phosphoryl lock c src inact state find repres crucial step toward ptm inspir drug design kinas famili | D015195 | T090 |
34,668,698 | conjug aztreonam synthet monocycl lactam antibiot siderophor mimet signific expand activ gram negat bacteria monocycl lactam antibiot activ first synthes year ago extens earli structur activ relationship sar studi especi emphas need heteroatom activ monocycl lactam led studi oxamazin monobactam monosulfactam monocarbam various side chain peripher substitut reveal potent activ select strain gram negat bacteria aztreonam still clinic use monobactam notabl activ mani gram negat bacteria limit activ problemat multidrug resist mdr strain pseudomona aeruginosa acinetobact baumannii herein report extens side chain aztreonam toler especi coupl side chain free acid bis catechol siderophor mimet signific improv activ mdr strain gram negat bacteria signific concern | D001398;D008997 | T195;T109 |
34,668,697 | nonphysiolog reduct sodium dithionit fefe hydrogenas influenc enzym mechan fefe hydrogenas high activ enzym interconvert proton electron hydrogen h activ site h cluster form canon fe cluster fe h coval attach uniqu fe subclust fe h site redox activ heterolyt split format h take place fe h fe h store electron detail catalyt mechan enzym intens investig two domin model exist literatur one model altern form activ oxid state h ox name h ox h form low ph presenc nonphysiolog reduct sodium dithionit nadt believ play crucial role h ox h previous suggest proton fe h show h ox h form simpl addit sodium sulfit na domin oxid product nadt low ph low ph requir indic sulfur dioxid speci involv spectroscopi support bind near fe h caus redox potenti increas mv potenti shift detun redox potenti subclust h cluster lower activ shown protein film electrochemistri pfe togeth result indic h ox h one electron reduc counterpart h red h artifact use nonphysiolog reduct crucial catalyt intermedi propos renam state dithionit dt inhibit state h ox dt h red dt broader potenti implic use nonphysiolog reduct spectroscop mechanist studi enzym highlight | D055162 | T070 |
34,668,694 | discoveri next generat tropomyosin receptor kinas inhibitor combat multipl resist associ protein mutat tropomyosin receptor kinas trk inhibit effect therapeut approach treatment varieti cancer despit use first generat trk inhibitor trki larotrectinib result signific therapeut respons patient acquir resist develop invari emerg secondari mutat occur solvent front xdfg gatekeep region trk repres common mechan acquir resist howev xdfg mutat remain insensit second generat macrocycl trkis selitrectinib repotrectinib design overcom resist mediat solvent front gatekeep mutat report structur base drug design discoveri next generat trki structur activ relationship studi culmin identif promis drug candid show excel vitro potenc panel trk mutant especi trka gc xdfg motif improv vivo efficaci trk wild type mutant fusion driven tumor xenograft model respect | D055808 | T062 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.